{"id":125267,"date":"2025-05-23T12:45:08","date_gmt":"2025-05-23T12:45:08","guid":{"rendered":"https:\/\/www.europesays.com\/uk\/125267\/"},"modified":"2025-05-23T12:45:08","modified_gmt":"2025-05-23T12:45:08","slug":"us-approves-china-invented-painkiller-that-could-reduce-fentanyl-overdoses","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/uk\/125267\/","title":{"rendered":"US approves China-invented painkiller that could reduce fentanyl overdoses"},"content":{"rendered":"<p>The US Food and Drug Administration (FDA) has approved the first China-invented painkiller designed as a non-opioid alternative, giving it the potential to curb <a target=\"_self\" class=\"e1yy41x40 ef9u0v01 css-1ankfgb ecgc78b0\" href=\"https:\/\/www.scmp.com\/topics\/fentanyl-and-other-opioids?module=inline&amp;pgtype=article\" title=\"\" data-qa=\"BaseLink-renderAnchor-StyledAnchor\" rel=\"noopener\">fentanyl-related<\/a> overdose deaths.<\/p>\n<p datatype=\"p\" data-qa=\"Component-Component\" class=\"e8zc9q40 css-1c6uqr6 ec74h0k1\">Qamzova, developed by Nanjing-based biotech firm Delova, is the world\u2019s first long-acting injectable analgesic \u2013 offering 24-hour pain relief through a single daily injection and marking a milestone for China\u2019s growing pharmaceutical industry.<\/p>\n<p datatype=\"p\" data-qa=\"Component-Component\" class=\"e8zc9q40 css-1c6uqr6 ec74h0k1\">The non-steroidal anti-inflammatory (NSAID) medication belongs to the same group of painkillers as aspirin and ibuprofen. It contains a high concentration of meloxicam, a compound commonly used to reduce pain and inflammation.<\/p>\n<p>According to <a target=\"_self\" class=\"e1yy41x40 ef9u0v01 css-1ankfgb ecgc78b0\" href=\"https:\/\/www.scmp.com\/topics\/sino-biopharmaceutical?module=inline&amp;pgtype=article\" title=\"\" data-qa=\"BaseLink-renderAnchor-StyledAnchor\" rel=\"noopener\">Sino Biopharmaceutical<\/a>, the Chinese conglomerate that owns the commercial rights to Qamzova, clinical trials showed it was effective in reducing post-surgical reliance on opioids.<\/p>\n<p datatype=\"p\" data-qa=\"Component-Component\" class=\"e8zc9q40 css-1c6uqr6 ec74h0k1\">By providing a safer, long-acting treatment for moderate-to-severe pain, Qamzova directly addresses the US overdose epidemic fuelled by addictive opioids, including fentanyl \u2013 a synthetic drug linked to tens of thousands of deaths annually.<\/p>\n<p datatype=\"p\" data-qa=\"Component-Component\" class=\"e8zc9q40 css-1c6uqr6 ec74h0k1\">Qamzova\u2019s arrival underscores China\u2019s rising role in innovative medicines development while offering healthcare professionals a critical tool to mitigate opioid dependency risks and improve patient recovery.<\/p>\n","protected":false},"excerpt":{"rendered":"The US Food and Drug Administration (FDA) has approved the first China-invented painkiller designed as a non-opioid alternative,&hellip;\n","protected":false},"author":2,"featured_media":125268,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4315],"tags":[55530,1395,55529,2460,4428,105,55527,4326,55526,4427,55533,55532,55531,55525,55528,10741,55534,16,15],"class_list":{"0":"post-125267","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-medication","8":"tag-american-psychiatric-association","9":"tag-china","10":"tag-delova","11":"tag-fda","12":"tag-fentanyl","13":"tag-health","14":"tag-li-jianhua","15":"tag-medication","16":"tag-meloxicam","17":"tag-morphine","18":"tag-nanjing","19":"tag-national-medical-products-administration","20":"tag-non-opioid","21":"tag-opioid","22":"tag-qamzova","23":"tag-shanghai","24":"tag-sino-biopharmaceutical","25":"tag-uk","26":"tag-united-kingdom"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/114557217998350158","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/125267","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=125267"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/125267\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/125268"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=125267"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=125267"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=125267"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}